Multiple Myeloma: Treatment is Getting Individualized
Open Access
- 26 July 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Indian Journal of Hematology and Blood Transfusion
- Vol. 32 (1), 3-9
- https://doi.org/10.1007/s12288-015-0575-5
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Diagnosis and Risk Stratification in Multiple MyelomaHematology/Oncology Clinics of North America, 2014
- Molecularly Targeted Therapies in Multiple MyelomaLeukemia Research and Treatment, 2014
- Clinical impact of chromosomal aberrations in multiple myelomaJournal of Internal Medicine, 2010
- Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myelomaBritish Journal of Haematology, 2010
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted MyelomaJournal of Clinical Oncology, 2010
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myelomaBlood, 2009
- Role of B-Cell–Activating Factor in Adhesion and Growth of Human Multiple Myeloma Cells in the Bone Marrow MicroenvironmentCancer Research, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Hypodiploidy is a major prognostic factor in multiple myelomaBlood, 2001
- Interphase fluorescence in situ hybridization (FISH) as a powerful tool for the detection of aneuploidy in multiple myeloma.1995